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Background: Human breast cancer is a heterogeneous disease classified by molecular subtyping into luminal A,
luminal B, HER2-overexpressing, basal-like, claudin-low and normal-breast like. The routinely applied and
standardized immunohistochemical-based surrogates of this classification group together the last three entities
as triple-negative breast cancer (TNBCs) that show the most diverse and complex heterogeneity and represent a
therapeutic challenge.
In the present work 156 feline mammary lesions consisting of feline mammary carcinomas (FMCs), benign
neoplasms, and hyperplastic/dysplastic tissues were evaluated histologically and by immunohistochemistry for
expression of basal and luminal cytokeratins (CK), vimentin, alpha-smooth muscle actin, calponin, estrogen receptor
(ER) alpha (a), and progesterone receptor (PR). Thirty-seven FMCs with 27 matched non-neoplastic controls were
also investigated for gene expression of ERa, ER beta, PR, and HER2.
Results: A large group of hormone receptors (HRs)-negative aggressive carcinomas - that did not overexpress
HER2 - could be distinguished from the less aggressive (10.8%) and benign (8%) HRs + tumors, that showed bilineage
(luminal and myoepithelial) differentiation. Immunohistochemical evaluations of cytoplasmic filaments indicated that
HRs- FMCs are vimentin+, CK14+, and CK5_6+ carcinomas that may resemble the TNBCs (basal like/claudin low)
described in women. The identification of luminal and myoepithelial progenitors within the mammary ductal system
suggested potential cells/sites of origin of these tumors. A diffuse and never previously described CKs/vimentin luminal
cell co-expression was detected in the non-neoplastic ducts, indicating a potential bilineage progenitor.
Conclusions: These results indicate and potentially explain the high incidence of triple-negative, vimentin +
aggressive tumors in cats that may used to elucidate some of the challenging features of TNBCs in women.
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Human breast cancer (HBC) is a heterogeneous disease
that still leads to more than 120.000 expected deaths per
year [1]. One of the explanations for the high mortality
rate is the complexity of the cellular components of the
normal breast and the associated molecular mutations.
By molecular analyses several distinct “intrinsic” HBC sub-
types have been identified (i.e. luminal A, luminal B, HER2-* Correspondence: Valentina.zappulli@unipd.it
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unless otherwise stated.overexpressing, basal-like, claudin-low, and normal-breast
like) [2-4].
Because of the complexity and costs of gene expres-
sion profiling, immunohistochemical (IHC) surrogates of
the molecular subtypes are routinely assessed [4,5].
Guidelines for IHC markers (i.e. ER, PR, HER2, Ki67)
evaluation are continuously under discussion to stratify
breast cancer patients in a clinical context for prognostic
and treatment selection purposes [6-8]. When applying
both clinical and IHC analysis to HBC a group of “triple
negative” cancers (TNBCs) (lacking ER, PR, and HER2)
is identified [9]. TNBCs constitute 10-20% of all HBCs,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cinomas, lack a specific targeted therapy, and are a het-
erogeneous group of breast tumors [10]. Approximately
70-75% of TNBCs share similarities with the basal-like
breast cancer (BLBC) molecular subtype; therefore they
have been considered erroneously as synonyms [9]. His-
tologically, the majority of TNBCs are invasive ductal
carcinomas but medullary, metaplastic, and adenoid cystic
histological subtypes share the triple negativity despite a
more favorable prognosis [11]. Using transcriptome ana-
lysis distinct classes of TNBCs have been recognized: the
BLBCs, the normal breast-like HBCs, and the newly iden-
tified claudin-low subtype [12,13], but further efforts dis-
sected even more distinct TNBCs signatures [10].
At present, there is no standardization of IHC markers
able to identify the TNBCs classes. BLBCs show expres-
sion of basal cytokeratins (CK5/6 and/or CK17 and/or
CK14), epidermal growth factor receptor (EGFR), C-kit
(CD117), and a high frequency (80%) of p53 mutation
[12]. In contrast, claudin-low tumors show epithelial-to-
mesenchymal transition (EMT) features, immune system
responses, and stem cell-associated biological markers
[13]. Many researchers have speculated that the genomi-
cally defined HBC subtypes may represent transformation
of stem cells with arrest at specific stages of development
or, alternatively, direct transformation of various mature
cell types [3,5,14]. Data suggest that invasive HBCs may
be placed on a normal mammary differentiation hierarchy
and in this hypothetical view of developmental origin the
claudin-low class would be considered as the most primi-
tive subtype [3].
In the feline species, mammary cancer is a leading
cause of death and the most common tumor in female
cats (queens). Feline mammary tumors (FMTs) are fre-
quently high-grade invasive carcinomas (80-90%) that
lack a well-differentiated tumor-suppressor myoepithe-
lial component which is much more common in canine
mammary tumors [15,16]. Although there are no robust
and standardized results for hormone receptors (HRs)
and HER2 positivity, feline mammary carcinomas (FMCs)
often lack significant levels of ERa and PR [17-23]. In
addition, FMCs have been associated with decreased ex-
pression of adhesion molecules [24] and high expression
of basal cytokeratins and vimentin [25], and a “basal-like”
subtype was identified by IHC-analyses [17].
Further demonstration of these interesting similarities
between FMCs and TNBCs might offer relevant infor-
mation in veterinary medicine and might support FMC
as a useful spontaneous model for pathogenetic mecha-
nisms and therapeutic approaches [17,18,26], overcoming
some of the limitations of HBC cell-line based studies and
mouse modeling [27-30].
The aim of this study was to determine the immuno-
histochemical and molecular features of non-neoplasticmammary gland tissue and FMTs in term of HRs, HER2,
and cytoplasmic filaments expression and to provide
additional information on the possible origin of HRs-
vimentin + FMTs that may be useful for further analyses
of HBC.Methods
Samples collection and follow-up data
The present IHC and molecular study was conducted on
a population of 81 queens with mammary gland lesions.
For IHC analysis paraffin-embedded samples, submitted
to the Diagnostic Service of Veterinary Anatomical Path-
ology (University of Padua, Italy) routinely collected dur-
ing surgery and processed as previously described [22],
were used. Distant metastases were not reported at the
time of diagnosis. In addition, for 37/81 cases a portion
(approx. 4 × 4 × 6 mm) of enlarged mammary tissue was
collected at the time of surgery and was stored in RNA
Later (Ambion, Austin, TX) (−80°C). Twenty-seven sam-
ples of adjacent presumed normal mammary parenchyma
(matched controls) were also collected immediately after
surgery as the adjacent portion of the presumptive tumor
with no further sampling for the subject and identically
stored.
Data on the one-year post-surgical survival and the de-
velopment of local relapses and distant metastases were
available for 43 subjects. Twenty-two of 40 cats (55%)
with malignant tumors were dead within the first year
after surgery; 12/40 (30%) of the cats had visceral metas-
tases and 17/40 (42.5%) had local recurrences.Histopathology
Histological evaluation of the paraffin-embedded sam-
ples from the 81 subjects was performed by two or more
ECVP-certified pathologists. Morphological diagnoses
were based on the WHO classification [15] and on the
recent literature [16,31] that describes new mammary
tumor subtypes that includes the new categories of come-
docarcinoma, ductal adenoma/carcinoma, and intraductal
papillary adenoma/carcinoma. The ductal and intraductal
papillary (“ductal-associated”) tumors were confirmed by
IHC as biphasic (see later). Criteria of malignancy were:
significant nuclear/cellular pleomorphism, presence of
random areas of necrosis, and mitotic index (MI). The MI
was calculated as the total number of mitoses per 10 high
power fields (40×, Olympus BX40) in the areas with the
highest proliferative activity. A MI > 3 was used as cut-off
for malignancy in borderline (benign vs malignant)
lesions. Grading of malignant tumors was performed
using the modified Elston and Ellis [32] system [33].
Peritumoral lymphatic invasion was also assessed. Before
RNA extraction half of the RNA Later-preserved sample
was embedded in paraffin for histological evaluation.
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Four-micron-thick sections were cut, mounted on
Superfrost®Plus microscope slides (Menzel GmbH,
Braunschweig, Germany) and dried at 37°C for 30 mi-
nutes. IHC evaluations for cytokeratins (CK) CK5-6,
CK14, CK8-18, panCK, calponin (CALP), vimentin
(VIM), alpha-smooth muscle actin (aSMA), ERa, and
PR were performed using an automated immunostainer
(BenchMark XT®, Ventana Medical System Inc., Tucson,
AZ). See Table 1 for specific primary antibodies and proto-
cols. The incubation temperature for all the antibodies
was 40°C and the ultraView Universal DAB detection Kit
was applied (Ventana Medical System Inc., Tucson, AZ).
Internal positive controls were the epidermis, adnexal
epithelium, the non-neoplastic mammary glands (panCK,
CK5_6, CK14, CK8_18), and vessels wall (CALP and
aSMA). Sections of feline uterus were used as positive
controls for ER and PR.
For all markers positivity was evaluated as the percent-
age of positive neoplastic cells counted in at least 10
random high-power fields (40×), avoiding necrotic areas
and the immediately adjacent portions, for a total of
1,000 cells. Specifically, nuclear positivity was evaluated
for ERa and PR, and samples were considered positive
if >1% cells were stained, whereas cytoplasmic brown
staining was considered as positive for CK5_6, CK14,Table 1 Antibodies and details of the protocols applied for th
Markers Antibodies (mouse anti-human)
clone and producer
Cytokeratin 5/6 Clone D5/16 B4
Dakocytomation










α-smooth muscle actin Clone 1A4
Dakocytomation
Estrogen receptor NCL-ER-6 F11
Novocastra
Progesteron receptor Clone: PR10A9
Immunotech
CCR, cell conditioning reduced: 30 minutes at 95°C; CCS, cell conditioning standard
*The primary antibody was diluted in the Antibody Diluent (Ventana Medical System
**Incubation time for primary antibody; min, minutes.CK8_18, panCK, CALP, VIM, and aSMA. For the latter
markers the morphology and location of positive cells
was determined, and a positive sample cut-off was not
established.
Light microscopic evaluation of each marker was con-
ducted in a blinded manner. Consensus was achieved with
a third pathologist in discordant cases. Positivity was eval-
uated separately for all types of lesions (malignant, benign,
hyperplastic) and the normal mammary tissue.
RNA extraction and sequencing
Samples preserved in RNA Later (approx. half of the
sample) including 37 tumoral and 27 normal glands, ho-
mogenized in Trizol Reagent (Invitrogen, Carlsbad CA)
and total RNA isolation was completed following the
manufacturer’s protocol. The extracted RNAs were
treated with RQ1 RNAse-free DNAse (Promega, Madison,
WI) and purified with a standard phenol–chloroform
extraction.
One microgram of total RNA from each sample was
reverse transcribed using a reverse transcriptase (Super-
script II, Life technologies Grand Island, NY) and ran-
dom hexamers to obtain first-strand cDNA. The cDNA
was then used as a template for quantitative real-time
PCR to evaluate the relative expression of ERa, ER beta
(b), PR, Erb-B2 genes in feline mammary lesions ande immunohistochemical examination
Dilution* Unmasking Incubation time**
1:100 CCR 24 min
+ protease 2 min
1:20 CCR 18 min
1:20 protease 8 min 24 min
1:100 CCR 16 min
1:200 CCR 12 min
1:100 CCR 18 min
1:100 no 10 min
1:40 CCS 14 min
1:100 CCE 18 min
: 60 minutes at 95°C; CCE, cell conditioning extended: 90 minutes at 95°C.
Inc., Tucson, AZ).
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designed using the Assay-by-design service (Life Tech-
nologies, Grand Island, NY) based on the coding se-
quences of the feline ERa, ERb, PR, Erb-B2 as target
genes and b-Glucuronidase (b-Glu) as the reference gene
(Acc. Num. AY605260, HE608843, JX965384, AY702651,
AF012423). An aliquot (2.5 μl) of diluted (1:50) cDNA
template was amplified in a final volume of 10 μl, con-
taining 5 μl of TaqMan® Universal PCR Master Mix (Life
technologies Grand Island, NY). The amplification
protocol consisted of an initial step of 2 min at 50°C and
10 min at 95°C, followed by 45 cycles of 10 s at 95°C
and 30 s at 60°C. All experiments were carried out in a
ABI PRISM 7000 (Life technologies Grand Island, NY).
For each sample, the Ct (Cycle threshold) was used to
determine the relative amount of target gene; each
measurement was made in triplicate, and normalized to
the reference gene b-Glu, which was also measured in
triplicate.
A target gene fold-change (FC) value was finally cal-
culated for each sample using the ΔΔCp method
(ΔCptarget-reference sample - ΔCptarget-reference calibrator)
using cat ovarian cDNA as calibrator.
Statistical analysis
Statistical analysis of IHC and molecular expression pro-
files and correlation with histological parameters and
follow-up data were performed with the SPSS advanced
statistical package 13.0 (SPSS Inc., Chicago, Illinois). The
Spearman correlation test, the Kruskal-Wallis test, the
Mann Whitney test, the Wilcoxon test, the Wilcoxon
test for paired samples and the sign test were performed.
The level of significance was fixed at P < 0.05.
Results
Clinical data and histopathology
Mean age of the female cats (n = 81) was 11.6 years
(range 1 to 18 years). No significant differences were
found between the mean age of animals carrying benign
(11.5 years) and malignant neoplasms (12 years). Domes-
tic short hair cats (77.7%) were the most common breed
and only 4 Siamese cats were present with a mean age
of 14 years. Forty-seven cats were ovariectomized but
unfortunately the age at ovariectomy was known only
for 10 cats (mean age 7.8 years, range 1 to 12 years, only
one cat ovariectomized at 1 year of age).
Histopathology was performed on 156 lesions: 77 ma-
lignant lesions (93% of the tumors) (68 primary mam-
mary malignant tumors and 9 lymph node metastases),
6 benign tumors (7% of the tumors), and 73 hyperplas-
tic/dysplastic lesions. Among the malignant tumors, the
tubular (22/68, 32%) and the tubulopapillary (18/68,
26.5%) carcinomas were the most common. In addition,
10/68 comedocarcinomas (15%), 6/68 ductal carcinomas(9%), 4/68 solid carcinomas (6%), 3/68 squamous cell
carcinomas (4.5%), 2/68 cribriform carcinomas (3%), 2/68
intraductal papillary carcinomas (3%), and 1/68 carcinoma
in-situ were observed. Using the modified Elston and Ellis
[32] grading system 20 carcinomas were grade I, 22 were
grade II, and 26 were grade III. All “ductal-associated”
carcinomas were grade I. Seventeen grade III (65%)
mammary carcinomas were associated with peritumoral
lymphatic invasion. Benign tumors were two ductal
adenomas, two fibroadenomas, and two intraductal pap-
illary adenomas. The most frequently diagnosed hyper-
plastic/dysplastic lesions were lobular hyperplasia (27/
73, 37%), duct ectasia (27/73, 27%), and duct hyperplasia
(19/73, 26%). Normal mammary parenchyma was present
at the periphery of 8 lesions.
Detailed histopatological evaluation of the RNA Later-
preserved samples was not possible but histopathology
confirmed the presence of a highly cellular cohesive
population of cells in all the 37 cases diagnosed as
malignant. More regular and loosely arranged lobular/
ductal structures were identified in the 27 samples of the
presumptive normal mammary glands.
IHC evaluations
All 156 lesions and the normal tissues showed 100%
positive staining to panCK of the epithelial cells (except
one metastasis with 37% panCK + cells). CALP and
aSMA were never detected in the luminal epithelial cells.
The other IHC results are summarized in Table 2.
Of the hyperplastic/dysplastic tissues 28 cases were
ERa-/PR-; only one specimen had normal non-hyperplastic
associated mammary tissue that was also ERa-/PR-.
Twenty-five out of twenty-eight cases were adjacent to
HRs negative tumors and 3/28 cases were not associated
with a tumor. There was no association between HRs-
status and ovariectomy.
Both in normal and hyperplastic/dysplastic tissues
CK8_18 was diffusely expressed in luminal cells (with
the exception of the single case of epitheliosis) (Figure 1a).
In all cases, VIM was co-expressed with CK8_18 in the lu-
minal compartment of both interlobular and intralobular
ducts (Figure 1a,b). In the hyperplastic lobules CK14 was
observed in luminal cells exclusively in the terminal por-
tion of the intralobular ducts (Figure 1c). CALP, aSMA,
and VIM diffusely stained basal (myoepithelial) cells from
the ducts to the lobules, whereas CK14 and CK5_6 were
evident at the same basal location, but only in the inter-
lobular and intralobular ducts (Figure 1c,d).
At IHC “ductal-associated” tumors were confirmed
by the presence of basal/myoepithelial cells that were
CK8_18-/panck + low/CK14+/CK5_6+/CALP+/aSMA+/
VIM + (Figure 2a,b,c,d) in association with luminal
CK8_18+ cells (Figure 2a) (biphasic tumors) as previ-
ously described (Zappulli et al. [28]).
Table 2 Expression of markers in luminal neoplastic cells examined by immunohistochemistry
No. Grading PR ERα CK8_18 VIM CK5_6 CK14
Percentages of + luminal epithelial cells: Mean ± SD (number of positive samples, range of positive cells)
Normal
yglands
8 24 ± 24.60 (5, 25–72) 38 ± 29 (6, 22–70) 100 ± 0 (8) 100 ± 0 (8) (ductal) - 100 ± 0 (8) (terminal intralobular ducts)
Hyperpasia/
dysplasia
73 5.59 ± 17 (13, 2.10-87) 10.58 ± 25.54 (25, 1.30-100) 100 ± 0 (73) 100 ± 0 (72)c (ductal) - 100 ± 0 (29)e (terminal intralobular ducts)
Benign
tumors
6 15.55 ± 17.47 (3, 27–38) 26.97 ± 38.23 (4, 6–100) 100 ± 0 (6) 42.58 ± 36.62 (5, 7.5-100) - -
Malignant
tumors
68 1.54 ± 9.18 (3, 4.80-70) 2.85 ± 13.86 (6, 2–87.3) 83.45 ± 30.22 (65, 2–100) 53.19 ± 34.73 (62, 0.5-100) 7.76 ± 17.83 (29, 0.5-100) 32.05 ± 32.96 (62, 0.5-100)
DC/IDPC 8 I (1, 4.80%)a 12.38 ± 25.42 (4, 2–73) 100 ± 0 (8) 27.31 ± 28.48 (5, 17.8-80) - (1, 34%)f
Other
subtypes
12 I (1, 70%)b (1, 7%)b 72.67 ± 32.35 (11, 33–100) 51.41 ± 37.74 (11, 1.2-100) 5.69 ± 16.83 (6, 5–56) 32.10 ± 36.62 (9, 0.5-100)
22 II - - 87.18 ± 25.39 (22, 5–100) 57.85 ± 32.88 (21, 7–98) 6.98 ± 10.06 (5, 0.5-28) 37.91 ± 29.96 (22, 0.5-100)
26 III (1, 29.70%)b (1, 87.30%)b 78.96 ± 35.79 (24, 2–100) 58.04 ± 34.80 (25, 3.3-100) 12.37 ± 25.39 (17, 0.5-100) 35.49 ± 33.84 (23, 0.5-100)
LN Metastases 9 - - 81.33 ± 35.62 (9, 2–100) 50.83 ± 42.42 (9, 0.5-98) 5.33 ± 12.16 (3, 0.5-32.7) 28.47 ± 35.47 (9, 0.5-97)
SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; DC, ductal carcinoma; IDPC, intraductal papillary carcinoma; LN, lymph node; a One case of DC; bOne different case of tubulopapilary carcinoma


















Figure 1 Hyperplastic mammary gland, feline. IHC, DAB chromogen, hematoxylin counterstain, 5x; A) diffuse expression of CK8_18 in luminal
cells of lobules and ducts (*); B) vimentin expression in the luminal compartment of both interlobular (*) and intralobular ducts (arrow and 40x
inset); C) CK14 staining observed in luminal cells exclusively in the terminal portion of the intralobular ducts (40x inset) and basal location of the
interlobular (*) and intralobular ducts; D) CK5_6 positivity detected at basal location of the interlobular (*) and intralobular ducts.
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HRs (2 ERa+/PR+; 2 ERa+/PR-; 1 ERa-/PR+) (Figure 2e).
The ERa-/PR- intraductal papillary adenoma had adja-
cent non-neoplastic tissue that was also ERa-/PR- and
100% of the luminal neoplastic cells were VIM + in this
case. VIM was totally found in 5/6 benign tumors in
42.6% of luminal neoplastic cells, as average (range 7.5-
100%) (Figure 2b).
In the FMCs significant differences were found be-
tween the “ductal-associated” carcinomas and the “non-
ductal-associated” carcinomas. Five out of eight (62.5%)
malignant “ductal-associated” tumors were either ERa +
(Figure 2f ) or PR + in the luminal compartment that
showed neither CK5_6 nor CK14 IHC expression. Only
one HRs- ductal carcinoma showed luminal CK14 ex-
pression (34% cells). Luminal VIM was observed in 5/8
cases (62.5%), they were PR- and either ERa + or ERa-.
Similarly to benign tumors and non-neoplastic tissues
they were all positive to CK 8_18 in the luminal cells.
In “non-ductal-associated” FMCs, only 4 cases (6%)
were HR positive (7% ER+ + cells, 29.70% PR + cells, 70%
PR + cells, 87.3% ER+ + cells, respectively). All these sam-
ples were negative for luminal expression of CK5/6. Lu-
minal VIM was present in all (16%, 21%, 80%, and 98% +
cells, respectively), and one case was CK14+ (19% luminal
cells with 98% VIM+). They all showed 100% CK8_18+
neoplastic luminal cells. In the 94% of the ERa-/PR- FMCsa loss of CK8_18 was found (Figure 3a), whereas there
was increased VIM, CK5_6, and CK14 expression
(Figure 3b,c,d). 13/29 (45%) and 41/61 (67%) “non-ductal
associated” FMCs showed >10% neoplastic CK5_6+ and
CK14+ cells, respectively. VIM and CK5_6 expression in-
creased progressively with the grade. The nine metastases
showed a pattern of expression similar to ERa-/PR- FMCs
for all the markers.
Statistical analyses showed that ERa and PR expression
was significantly decreased in FMCs when compared to
benign tumors, hyperplastic/dysplastic lesions, and nor-
mal tissue, and when compared to paired samples (P <
0.01). CK8/18 was the only other marker that showed a
significant decrease in FMCs when compared to benign/
non-neoplastic lesions. Positive correlations were found
between ERa and both PR and CK8_18 (P < 0.01) and
between CK14 and CK5_6 (P < 0.05). A negative correl-
ation was identified between ERa expression and tumor
grade (P < 0.01). No significant associations were found
with survival and other histopathological parameters.
mRNA evaluations
In all the examined tissues ERa, ERb, PR and HER2 were
all expressed, despite large variances among samples
(Table 3). The ERa and PR gene expression were signifi-
cantly decreased (P < 0.0001 and P < 0.01, respectively) in
FMCs compared to matched non-neoplastic mammary
Figure 2 Mammary gland, feline. IHC, DAB chromogen, hematoxylin counterstain, 10x; A-E) Intraductal papillary adenoma (“ductal-associated”
FMT): A) CK8_18- basal/myoepithelial cells and CK8_18+ luminal cells, B) VIM + basal/myoepithelial (100%) and luminal (55%) cells, C) CK14+
basal/myoepithelial cells, D) CK5_6+ basal/myoepithelial cells; E) ER expression in luminal cells (100%); F) Intraductal papillary carcinoma
(“ductal-associated” FMT), ER expression in luminal epithelial cells (70%).
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tween tumoral and non-tumoral matched samples. A
positive correlation was found exclusively between ERα
and PR gene expression both in FMTs (P < 0.001) and in
non-neoplastic mammary glands (P < 0.05). Furthermore,
ERα expression was negatively correlated with tumor
grade (P < 0.05) while for PR the negative correlation was
only close to significance (P = 0.06).
Discussion
In this study we present data on the phenotypic and
prognostic markers expression in FMTs and associated
normal/hyperplastic/dysplastic glands. We found two
tumor subgroups: i. less aggressive biphasic HRs +
(“ductal-associated”) tumors and ii. more common and
aggressive HRs- heterogeneous carcinomas. We comparedproteins levels as detected by IHC with mRNA levels of
HRs and we determined ERβ and HER2 expression by
RT-PCR in matched samples. We demonstrated the distri-
bution of cell subtypes – both luminal epithelial and
basal/myoepithelial lineages – in non-neoplastic glands,
and found an unusual and previously undocumented
ductal luminal VIM positivity (co-expressed with CK8-18)
and a luminal CK14 expression specifically located in the
terminal intra-lobular ducts. Both CK14 and CK5_6 stain-
ing were increased in HRs- carcinomas.
In our study population (81 queens) the high ratio of
malignant (93%) versus benign tumors, the frequency of
invasive carcinomas of the tubular (28%) and tubulopa-
pillary subtypes (19%), and the relative low frequency of
ERα + and/or PR + FMCs correspond with the published
data [15,18,33].
Figure 3 ERaPR-simple tubular carcinoma, grade II, mammary gland, feline. IHC, DAB chromogen0, hematoxylin counterstain, 40x.
Expression in neoplastic cells of: A) CK8_18 (90%), B) VIM (35%), C) CK14 (70%), D) CK5_6 (28%).
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subtypes relies on ER, PR, HER2, and Ki-67 IHC labeling
and this represents a convenient shorthand substitute,
although not identical, to the molecular “intrinsic” sub-
types [34,35]. Nevertheless, wide variability of the per-
formance of these tests and inaccurate results (20%) are
still detected [6,36,37].
In veterinary medicine, the application of internation-
ally recognized guidelines has not yet been implemented
generating an even more imprecise picture of HRs status
in FMTs (<40% HRs + FMCs in most studies) [18,21,38].
When assessing the HRs expression by IHC in our feline
samples, we detected 12% of normal and 38% of hyper-
plastic/dysplastic glandular samples that were ER-/PR-;
these were always associated with HRs- tumors. Either a
technical artifact or a loss of hormone stimulation
should be considered as possible explanation for these
results. However, data regarding time of samples fixation
and age of ovariectomy, that might both affect HRsTable 3 RT-PCR fold-change values of markers
Feline mammary carcinomas (No. 37)
HER2 ERα ERβ
Median value 1.56 0.12 0.04
Variance 5.12 2.25 0.01
Range 0.13-10.1 0.01-8.32 0-0.38
ER, estrogen receptor alpha; PR, progesterone receptor; HER2, human epidermal groexpression, were not available for our samples. Never-
theless, our data support the idea that aggressive FMCs
tend to be HRs- (87%). Also, a progressive loss of HRs
expression from non-neoplastic to neoplastic samples as
well as from benign to malignant tumors was evidenced
in accordance with the literature [18,21,38]. In addition,
the subgroup of less aggressive grade I “ductal-associated”
carcinomas, defined as ductal and intraductal papillary
tumors by morphology and IHC [31], had an increased
frequency of ERa positivity when compared to all other
carcinomas. Furthermore, ERa and PR expression was
positively correlated with CK8_18, a marker of well-
differentiated luminal cells, and negatively correlated
with tumor grade as previously described [18,21], again
indicating of a loss of HRs in less differentiated and
more aggressive tumors.
We associated gene expression analysis to the IHC
evaluation of ERa and PR for a subset of samples. The
significant reduction of ERa and PR proteins in FMCsNormal mammary glands (No. 27)
PR HER2 ERα ERβ PR
0.03 2.16 1.63 0.03 0.31
0.34 7.68 4.33 0.01 3.10
0-3.39 0.59-10.93 0.05-9.94 0-0.43 0-7.40
wth factor receptor 2.
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tion for any subject-related variability.
In our work, we also studied ERb expression as already
done in HBC [39]. Similarly to HBC, in our feline sam-
ples, the ERb gene resulted expressed at very low levels
in all samples.
Data concerning HER2 status in FMTs are highly con-
troversial with values ranging from 5.5% to 90% of posi-
tive tumors probably due to different protocols and
evaluation methods [17,19,20,22,23,38,40]. In our work
we evaluated HER2 by RT-PCR and we found no signifi-
cant difference in HER-2 expression between FMCs and
matched non-neoplastic tissues. A more than 2-FC in-
creased was detected in 32% FMCs. Only one study ana-
lyzed the expression of HER2 mRNA in FMCs that was
3 to 18-FC increased in 6/11 tumors [19]. A previous
work from our group analyzed the IHC expression of
HER2, Ki-67, and p53 on the same FMTs samples used
in this study [22]. When we tested HER2 expression by
IHC and strictly applied the Food and Drug Administra-
tion (FDA)-approved HercepTest scoring system (DAKO,
Glostrup, Denmark) [41], only a single carcinoma scored
3+ [22]. This carcinoma demonstrated the highest RT-
PCR relative quantification of HER2 (single case with a
10-FC increase). Other authors tested HER2 IHC expres-
sion in FMTs, however variability of methods of assess-
ment makes comparison non-robust [17,19,23,41]. Our
data suggests that when strict criteria for HER2 assess-
ment (3+) are used, there are a few cases of HER2-
overexpressing FMTs.
On the basis of these and previous results [22] the ma-
jority of our FMTs samples had therefore a “triple-nega-
tive” phenotype (1/6 benign and 58/68 (85%) malignant).
In humans, there is no consensus on the stratification
of TNBCs due to their complex heterogeneity [9,13].
IHC-based surrogates have been discussed to diagnose
the TNBCs classes (BLBCs, claudin-low, and normal
breast-like) [13].
In our “triple-negative” FMCs we evidenced the ap-
pearance of CK5_6 in the 42.6% of the carcinomas
(7.8%, average of positive neoplastic cells) and CK14 in
the 91% of the carcinomas (32%, average of positive neo-
plastic cells), comparable to previous findings [17,25],
and possibly suggestive of a BLBC phenotype [17]. How-
ever, we were unable to demonstrate a significant p53
accumulation in the same dataset (13% of the FMCs)
[22], which should be a characteristic of BLBCs in
women [13].
A few studies have found decreased expression of ad-
hesion molecules in FMTs [24,25] suggesting a possible
EMT-based aggressive phenotype, which is reported for
the claudin-low subclass [13]. In the present work, we
found vimentin expression (91% of the FMCs) in the
neoplastic cells (53% average) a feature also described inother studies [26,42,43]. Vimentin is considered a mes-
enchymal marker responsible for cell integrity and resist-
ance against stress [44] and its expression in HBC has
been addressed as a feature of the claudin-low pheno-
type [45-47]. However, its prognostic role in HBC in
term of both survival and metastases development is not
clear [45-48]. One study hypothesized that vimentin-
positive invasive HBCs have a direct myoepithelial histo-
genesis, or a EMT phenotype, or may derive from breast
progenitor cells with bilinear (luminal and myoepithelial)
differentiation potential [45].
This information would support a significant similar-
ity between the aggressive FMCs and the claudin-low
TNBC class.
Our findings on the cell lineages phenotype and distri-
bution in the non-neoplastic feline mammary gland (see
a schematic summary in Figure 4) provide useful in-
sights on the potential site/cell of origin of these aggres-
sive FMCs. We found two separate lineages, both with
precursor and terminally differentiated cells that had a
different distribution pattern in the non-neoplastic
glands. Terminally differentiated luminal (CK8_18+)
and myoepithelial (VIM+/CALP+/aSMA+) cells were
present within the lobules. The ductal system was charac-
terized by basal intermediate progenitors (VIM+/CK5_
6+/CK14+/CALP+/aSMA+) and luminal cells that dif-
fusely co-expressed CK8_18 and VIM. The subgroup of
“ductal-associated” tumors overlapped this dual (biphasic)
component and had a less aggressive (grade I) HRs +
phenotype, suggesting a more stable ductal-differentiation.
Exclusively and consistently at the ductal-lobular junc-
tion of the non-neoplastic glands (possibly terminal end-
buds region) the luminal cells stained with CK14. In the
more common, aggressive, predominantly triple-negative,
“non-ductal associated” FMCs the biphasic nature was not
present. A diffuse increase of CK14 and a moderate posi-
tivity to CK5_6 were observed.
As indicated by Figure 4, and similarly to what re-
ported for HBCs [3,5], all these data suggest that these
“non-ductal associated” FMCs arise at the ductal-lobular
junction where potential stem/progenitor cells (CK5_6+)
reside to expand the normal glandular lobules and are
capable to give rise to CK8_18+/CK14+/VIM + clones
responsible for the heterogeneity of these FMCs sup-
porting the idea that tumor arise from stem cells [5,14].
Two hypotheses are instead consistent for the less ag-
gressive “ductal-associated” FMTs. i) They might originate
at the same site, but progressing along a more differenti-
ated phenotype with no or minimal stem/progenitor con-
tent (CK5_6 negative). ii) Alternatively they might arise in
a more proximal ductal region from intermediate progeni-
tor cells (Figure 4).
There is very little data describing the co-expression of
cytokeratins (CK8_18) and vimentin in non-tumoral
Figure 4 Potential localization of mammary cell lineages and associated tumour origin. A) Hypothetical distribution of cell subtypes
within the feline mammary gland according to the immunohistochemical analyses for cytoplasmic filaments and associated presumptive cell/site
of origin of feline mammary tumors. B) Hypothetical lineage differentiation of feline mammary gland cell subtypes. (DT, ductal tumors; IDP,
intraductal papillary tumors; ER, estrogen receptor alpha; PR, progesterone receptor; CK, cytokeratin; vim, vimentin; CALP, calponin; SMA,
alpha-smooth muscle actin).
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productive tract) [49,50]. Usually their co-expression has
been associated with drug resistance, invasion and tumor
metastasis [48]. In the feline gland the coexpression of
cytokeratin and vimentin may indicate a non-terminally
differentiated luminal component that is diffusely dis-
tributed in the ducts, corroborating the hypothesis that
also vimentin positive HBCs (TNBCs) may originate
from a precursor cell with bilineage differentiationpotential and not from an EMT process [45]. This may
also explain why a small subset of the TNBCs are less-
aggressive histological subtypes and/or show myoepithelial
differentiation (i.e. metaplastic and adenoid cystic) [10].
Vimentin has never been described in the non-neoplastic
luminal epithelium of the mammary gland of any species,
however, it has been described in the so-called ‘cap cells’
of the mice and in the “side-population” of human breast
containing the progenitor cell compartment, further
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in the pathogenesis of vimentin-expressing breast cancers
[45]. A species-specific distribution of these progenitors
might explain why in cats mammary cancer is fre-
quently an aggressive, triple-negative, vimentin-positive
carcinoma.
Conclusions
Our study supports the hypothesis that FMCs are gener-
ally aggressive HRs negative cancers that manifest an
heterogeneous phenotype characterized by basal cytoker-
atins and vimentin expression. They appear similar to
the TNBCs, particularly to the claudin-low subclass and
they might originate from progenitor/precursor cells at
the ductal-lobular junction. A second subgroup of less
common and less aggressive “ductal-associated” FMTs
might instead originate from a hierarchically more ad-
vanced precursor or from a more distal ductal portion
with less stem progenitors. These results indicate that a
species-specific phenotype and distribution of cell line-
ages within the mammary gland might explain the devel-
opment of species-specific tumor subtypes. The feline
species might represent a good model to study a certain
type of HBC, to better understand cancer pathogenesis,
and to address novel targeted therapies.
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